LOGO
LOGO

Aquestive's Anaphylm - Will The Oral Investigational Epinephrine Product Breathe Easy?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Aquestive Therapeutics Inc. (AQST), which is developing the first and only non-device based, oral epinephrine product candidate for anaphylaxis, has a clinical trial catalyst to watch this quarter.

Anaphylaxis is a severe and rapidly occurring systemic hypersensitivity reaction that can be life-threatening. Primary triggers for reactions leading to anaphylaxis often involve medications, specific foods (such as peanuts), and insect sting venom.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -May 18 – May 22, 2026

May 22, 2026 14:46 ET
Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.

Latest Updates on COVID-19